Biomea Fusion Stock Buy Hold or Sell Recommendation
| BMEA Stock | USD 7.24 0.22 3.13% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Biomea Fusion is 'Strong Sell'. Macroaxis provides Biomea Fusion buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BMEA positions.
Check out Biomea Fusion Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide. In addition, we conduct extensive research on individual companies such as Biomea and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Biomea |
Execute Biomea Fusion Buy or Sell Advice
The Biomea recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biomea Fusion. Macroaxis does not own or have any residual interests in Biomea Fusion or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biomea Fusion's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Biomea Fusion Trading Alerts and Improvement Suggestions
| Biomea Fusion had very high historical volatility over the last 90 days | |
| Net Loss for the year was (117.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomea Fusion currently holds about 149.63 M in cash with (96.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11. | |
| Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Brokerages Set Biomea Fusion, Inc. Price Target at 30.50 |
Biomea Fusion Returns Distribution Density
The distribution of Biomea Fusion's historical returns is an attempt to chart the uncertainty of Biomea Fusion's future price movements. The chart of the probability distribution of Biomea Fusion daily returns describes the distribution of returns around its average expected value. We use Biomea Fusion price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biomea Fusion returns is essential to provide solid investment advice for Biomea Fusion.
| Mean Return | 0.05 | Value At Risk | -8.16 | Potential Upside | 9.12 | Standard Deviation | 4.76 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biomea Fusion historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biomea Stock Institutional Investors
| Shares | Northern Trust Corp | 2024-09-30 | 310.4 K | Two Sigma Investments Llc | 2024-09-30 | 273.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 244.7 K | Woodline Partners Lp | 2024-09-30 | 241.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 208.4 K | Rock Springs Capital Management Lp | 2024-09-30 | 181.1 K | Deutsche Bank Ag | 2024-06-30 | 178.2 K | Jane Street Group Llc | 2024-06-30 | 134.9 K | Wexford Capital Lp | 2024-09-30 | 130.3 K | Fmr Inc | 2024-09-30 | 5.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 3.6 M |
Biomea Fusion Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biomea Fusion or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biomea Fusion's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biomea stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.07 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 4.81 | |
Ir | Information ratio | -0.02 |
Biomea Fusion Volatility Alert
Biomea Fusion exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biomea Fusion's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biomea Fusion's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biomea Fusion Fundamentals Vs Peers
Comparing Biomea Fusion's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biomea Fusion's direct or indirect competition across all of the common fundamentals between Biomea Fusion and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biomea Fusion or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biomea Fusion's fundamental indicators could also be used in its relative valuation, which is a method of valuing Biomea Fusion by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biomea Fusion to competition |
| Fundamentals | Biomea Fusion | Peer Average |
| Return On Equity | -1.05 | -0.31 |
| Return On Asset | -0.56 | -0.14 |
| Current Valuation | 183.98 M | 16.62 B |
| Shares Outstanding | 36.24 M | 571.82 M |
| Shares Owned By Insiders | 25.01 % | 10.09 % |
| Shares Owned By Institutions | 64.50 % | 39.21 % |
| Number Of Shares Shorted | 9.41 M | 4.71 M |
| Price To Book | 3.45 X | 9.51 X |
| EBITDA | (124.62 M) | 3.9 B |
| Net Income | (117.25 M) | 570.98 M |
| Cash And Equivalents | 149.63 M | 2.7 B |
| Cash Per Share | 5.11 X | 5.01 X |
| Total Debt | 10.3 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 16.46 X | 2.16 X |
| Book Value Per Share | 2.10 X | 1.93 K |
| Cash Flow From Operations | (96.59 M) | 971.22 M |
| Short Ratio | 11.84 X | 4.00 X |
| Earnings Per Share | (4.01) X | 3.12 X |
| Target Price | 42.89 | |
| Number Of Employees | 107 | 18.84 K |
| Beta | -0.43 | -0.15 |
| Market Capitalization | 262.37 M | 19.03 B |
| Total Asset | 199.93 M | 29.47 B |
| Retained Earnings | (248.82 M) | 9.33 B |
| Working Capital | 156.32 M | 1.48 B |
| Net Asset | 199.93 M |
Note: Disposition of 25000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.84 subject to Rule 16b-3 [view details]
Biomea Fusion Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biomea . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Biomea Fusion Buy or Sell Advice
When is the right time to buy or sell Biomea Fusion? Buying financial instruments such as Biomea Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biomea Fusion in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Medical Equipment Thematic Idea Now
Medical Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biomea Fusion Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.01) | Return On Assets (0.56) | Return On Equity (1.05) |
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.